EMA backs datopotamab deruxtecan for advanced lung cancer

FDA approves datopotamab deruxtecan for EGFR-mutated lung cancer; EU lung-cancer application withdrawn

Datopotamab deruxtecan's regulatory path has split by region: the FDA granted accelerated approval for EGFR-mutated advanced lung cancer, while AstraZeneca and Daiichi Sankyo withdrew the EU lung-cancer application. For BD teams, investors, and analysts, the story now centers on US label durability, confirmatory data, and whether additional lung-cancer trials can sustain momentum in the absence of near-term EU positioning.

IntelligenceRegulatory Impact▾

EMA and FDA decisions frame this story. Regulatory relevance is high for lung cancer, with datopotamab deruxtecan and DATROWAY most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.

Regulatory split: FDA accelerated approval, EU lung-cancer withdrawal

The regulatory picture for datopotamab deruxtecan has split decisively by region. On June 23, 2025, the FDA granted accelerated approval to datopotamab deruxtecan-dlnk (DATROWAY) for adults with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. The indication is approved under accelerated approval based on objective response rate and duration of response.

In Europe, the trajectory diverged. AstraZeneca and Daiichi Sankyo voluntarily withdrew the marketing authorisation application (MAA) in the EU for datopotamab deruxtecan in the lung-cancer indication. The drug does hold European Union approval for the treatment of adult patients with unresectable or metastatic HR-positive, HER2-negative breast cancer who have received endocrine therapy, but the lung-cancer pathway has stalled.

For BD and investor teams tracking datopotamab deruxtecan's FDA label, the accelerated approval marks a concrete US lung-cancer asset. The EU withdrawal, however, narrows the near-term European commercial footprint and raises questions about the strength of the lung-cancer data package relative to the regulatory bar in each region.

IntelligenceCompetitive Intelligence▾

AstraZeneca and Daiichi Sankyo, Inc. are directly implicated. Competitive pressure reads medium — compare pipeline positioning and partnership scouting against signals in this story.

Key Takeaways

• The FDA granted accelerated approval to datopotamab deruxtecan-dlnk for EGFR-mutated NSCLC on June 23, 2025, based on objective response rate and duration of response in the EGFR-mutated post-therapy setting.
• AstraZeneca and Daiichi Sankyo withdrew the EU lung-cancer MAA, constraining near-term European positioning even though the drug is approved for HR-positive, HER2-negative breast cancer in the EU.
• TROPION-Lung01 remains the clinical anchor, showing that datopotamab deruxtecan significantly improved progression-free survival versus docetaxel in advanced/metastatic NSCLC, particularly in nonsquamous histology.
• Multiple Phase III lung-cancer trials are recruiting or active, including studies in TROP2-positive non-squamous NSCLC and first-line advanced NSCLC without actionable genomic alterations, indicating continued sponsor investment in potential future label expansion.

IntelligenceMarket Signals▾

Commercial pull is high and investment relevance high for lung cancer. Expect implications for pricing, access, and launch sequencing.

Clinical evidence: TROPION-Lung01 and the EGFR-mutated setting

The FDA accelerated approval rests on TROPION-Lung01, where Dato-DXd significantly improved progression-free survival (PFS) versus docetaxel in patients with advanced/metastatic NSCLC, driven by patients with nonsquamous histology. This trial serves as the clinical foundation for the current FDA label in the EGFR-mutated post-therapy population.

The accelerated approval pathway allows the FDA to grant approval based on a surrogate endpoint—in this case, objective response rate and duration of response—while the sponsor conducts a confirmatory trial to verify clinical benefit. For BD teams evaluating label durability and commercial potential, the key near-term question is whether confirmatory data will sustain or expand the current indication.

IntelligenceStrategic Takeaways▾

The FDA granted accelerated approval to datopotamab deruxtecan-dlnk for EGFR-mutated NSCLC on June 23, 2025, based on objective response rate and duration of response in the EGFR-mutated post-therapy setting. AstraZeneca and Daiichi Sankyo withdrew the EU lung-cancer MAA, constraining near-term European positioning even though the drug is approved for HR-positive, HER2-negative breast cancer in the EU. TROPION-Lung01

Pipeline: Recruiting and active trials in NSCLC

Datopotamab deruxtecan's lung-cancer pipeline extends beyond the current FDA label. A Phase III study of datopotamab deruxtecan versus docetaxel in previously treated TROP2-positive advanced or metastatic non-squamous NSCLC without actionable genomic alterations is currently recruiting. This trial broadens the potential addressable population by moving beyond the EGFR-mutated restriction and into TROP2-positive disease.

A Phase III, open-label, first-line study of Dato-DXd in combination with durvalumab and carboplatin for advanced NSCLC without actionable genomic alterations is active but not recruiting. This combination approach in the first-line setting represents a potential pathway for future label positioning in earlier treatment lines and broader patient populations.

A Phase II study of neoadjuvant and adjuvant treatment in resectable non-small cell lung cancer is recruiting, suggesting exploration of earlier disease stages. Together, these trials indicate that the sponsor is pursuing multiple potential pathways in NSCLC, even as the EU lung-cancer MAA remains withdrawn.

IntelligenceEvidence Quality▾

Grounded in 4 regulatory sources and 1 peer-reviewed source.

Investor and BD implications

The split regulatory outcome creates distinct market dynamics. In the US, datopotamab deruxtecan now has a labeled indication in a defined EGFR-mutated NSCLC population under accelerated approval. The pathway forward depends on whether confirmatory data support the clinical benefit needed for regular approval conversion and whether future trial readouts might support expansion into adjacent NSCLC populations.

In Europe, the withdrawn lung-cancer MAA narrows the asset's near-term commercial footprint to breast cancer. For investors and BD teams evaluating partnership or acquisition interest, the question becomes whether additional clinical data or a revised submission strategy might re-open the EU lung-cancer pathway, or whether the program's commercial focus will remain primarily US-driven in the near term.

For BD teams assessing competitive positioning, datopotamab deruxtecan now competes in the TROP2-directed antibody-drug conjugate (ADC) space in NSCLC as a labeled option in the post-therapy EGFR-mutated setting. The recruiting trials suggest potential future positioning in broader NSCLC populations and earlier treatment lines, contingent on trial success.

What to watch next

The immediate catalyst milestones for BD and investor tracking include:

• Confirmatory trial data supporting the accelerated approval and potential label conversion to regular approval.
• Readouts from NCT07291037 in TROP2-positive non-squamous NSCLC, which could potentially broaden the addressable population beyond EGFR-mutated disease.
• Data from NCT05687266 exploring first-line combination therapy, which could potentially support earlier treatment positioning.
• Any regulatory submissions or communications regarding re-engagement with the EMA on the lung-cancer indication.
• Data from a Phase IV prophylaxis study for datopotamab deruxtecan-related stomatitis, which addresses a known safety signal and may inform label management and patient selection strategies.

Regulatory context: Why accelerated approval matters

Accelerated approval is a regulatory pathway that allows the FDA to grant approval based on a surrogate or intermediate clinical endpoint reasonably likely to predict clinical benefit, rather than waiting for traditional efficacy measures like overall survival. This mechanism enables faster patient access to promising therapies while requiring the sponsor to conduct confirmatory trials. The current datopotamab deruxtecan approval is contingent on such confirmatory work, making trial progress a critical near-term catalyst for label durability.

Frequently Asked Questions

Related profiles

• AstraZeneca
• datopotamab deruxtecan
• datopotamab deruxtecan-dlnk
• dato-dxd

Related coverage

• AstraZeneca and Daiichi Sankyo datopotamab deruxtecan hits lung cancer endpoint
• FDA approves Keytruda for adjuvant NSCLC treatment, expanding Merck’s lung cancer label
• FDA approves Keytruda adjuvant NSCLC use in early-stage lung cancer